Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

PMID: 35046546
Journal: Genes and immunity (volume: 23, issue: 1, Genes Immun 2022 02;23(1):1-11)
Published: 2022-01-19

Decraene B, Yang Y, De Smet F, Garg AD, Agostinis P, De Vleeschouwer S


Immunogenic cell death (ICD) has emerged as a key component of therapy-induced anti-tumor immunity. Over the past few years, ICD was found to play a pivotal role in a wide variety of novel and existing treatment modalities. The clinical application of these techniques in cancer treatment is still in its infancy. Glioblastoma (GBM) is the most lethal primary brain tumor with a dismal prognosis despite maximal therapy. The development of new therapies in this aggressive type of tumors remains highly challenging partially due to the cold tumor immune environment. GBM could therefore benefit from ICD-based therapies stimulating the anti-tumor immune response. In what follows, we will describe the mechanisms behind ICD and the ICD-based (pre)clinical advances in anticancer therapies focusing on GBM.